RxDoctor Payments Data

Evgenia O Neil

Nurse Practitioner · Lewes, DENPI 1972992865

Payments from drug & device makers

$1,904in general payments, 2019–2025

Across 69 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$243
  • Ardelyx, Inc.$207
  • AstraZeneca$178
  • Mallinckrodt Hospital Products Inc.$176
  • Bayer$167
  • Amgen$165
  • plus $766 from 11 others

What the payments were for

  • Food & beverage$1,78494%
  • Education$1206%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,904 in reported general payments places this provider in the 85th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$52,104
Medicare patients
391
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide17$74,585
AuryxiaFerric Citrate12$43,636
JardianceEmpagliflozin22$26,014
VeltassaPatiromer Calcium Sorbitex23$22,604
FarxigaDapagliflozin Propanediol12$21,237
KerendiaFinerenone14$19,578
Sevelamer Carbonate39$4,911
Nifedipine ErNifedipine20$975
Olmesartan Medoxomil35$536
Carvedilol47$456
Losartan Potassium37$420
Calcitriol19$334
Amlodipine Besylate32$278
Furosemide17$80
Lisinopril15$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$16$43,63612 claims
Boehringer IngelheimJardiance$243$26,01422 claims
AstraZenecaFarxiga$178$21,23712 claims
BayerKerendia$167$19,57814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →